Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826272757157986304 |
|---|---|
| author | Wells, SA Robinson, BG Gagel, R Dralle, H Fagin, J Santoro, M Baudin, E Elisei, R Jarzab, B Vasselli, JR Read, J Langmuir, P Ryan, A Schlumberger, M |
| author_facet | Wells, SA Robinson, BG Gagel, R Dralle, H Fagin, J Santoro, M Baudin, E Elisei, R Jarzab, B Vasselli, JR Read, J Langmuir, P Ryan, A Schlumberger, M |
| author_sort | Wells, SA |
| collection | OXFORD |
| description | There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo. On objective disease progression, patients could elect to receive open-label vandetanib. The primary end point was progression-free survival (PFS), determined by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.Between December 2006 and November 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100). At data cutoff (July 2009; median follow-up, 24 months), 37% of patients had progressed and 15% had died. The study met its primary objective of PFS prolongation with vandetanib versus placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001). Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P = .001), and biochemical response (P < .001). Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65). A final survival analysis will take place when 50% of the patients have died. Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%).Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761). |
| first_indexed | 2024-03-06T22:17:37Z |
| format | Journal article |
| id | oxford-uuid:53f158b9-4aa6-496f-8bf3-e58948178853 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:17:37Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:53f158b9-4aa6-496f-8bf3-e589481788532022-03-26T16:34:44ZVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:53f158b9-4aa6-496f-8bf3-e58948178853EnglishSymplectic Elements at Oxford2012Wells, SARobinson, BGGagel, RDralle, HFagin, JSantoro, MBaudin, EElisei, RJarzab, BVasselli, JRRead, JLangmuir, PRyan, ASchlumberger, MThere is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo. On objective disease progression, patients could elect to receive open-label vandetanib. The primary end point was progression-free survival (PFS), determined by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.Between December 2006 and November 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100). At data cutoff (July 2009; median follow-up, 24 months), 37% of patients had progressed and 15% had died. The study met its primary objective of PFS prolongation with vandetanib versus placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001). Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P = .001), and biochemical response (P < .001). Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65). A final survival analysis will take place when 50% of the patients have died. Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%).Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761). |
| spellingShingle | Wells, SA Robinson, BG Gagel, R Dralle, H Fagin, J Santoro, M Baudin, E Elisei, R Jarzab, B Vasselli, JR Read, J Langmuir, P Ryan, A Schlumberger, M Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. |
| title | Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. |
| title_full | Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. |
| title_fullStr | Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. |
| title_full_unstemmed | Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. |
| title_short | Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. |
| title_sort | vandetanib in patients with locally advanced or metastatic medullary thyroid cancer a randomized double blind phase iii trial |
| work_keys_str_mv | AT wellssa vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT robinsonbg vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT gagelr vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT dralleh vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT faginj vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT santorom vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT baudine vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT eliseir vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT jarzabb vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT vassellijr vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT readj vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT langmuirp vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT ryana vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial AT schlumbergerm vandetanibinpatientswithlocallyadvancedormetastaticmedullarythyroidcancerarandomizeddoubleblindphaseiiitrial |